Welcome to Nektar’s Clinical Resources page. Here you can learn about our cancer research and development activities and our goal to potentially harness the immune system in the fight against cancer.
Please click on the thumbnails below to access the PDFs of the documents. If you have any questions, please contact firstname.lastname@example.org.
Bempegaldesleukin (BEMPEG; NKTR-214):
Bempegaldesleukin (an investigational first-in-class CD122-preferential IL-2 pathway agonist) in combination with a checkpoint inhibitor, leverages two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer.
Skin Cancer (1L Metastatic Melanoma and Adjuvant Melanoma):
A phase 3, randomized, open-label study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients with previously untreated, unresectable or metastatic melanoma
Bladder Cancer (1L Metastatic Urothelial Carcinoma (mUC) and Muscle Invasive Bladder Cancer (MIBC)):
Kidney Cancer (1L Advanced Renal Cell Carcinoma (RCC)):
Lung Cancer (1L Non-Small Cell Lung Cancer (NSCLC)):
NKTR-255 is an investigational IL-15 agonist that is designed to engage the IL-15 pathway to increase both NK cell proliferation and activation and proliferation and survival of CD8+ T cells.
Multiple Myeloma and Non-Hodgkin's Lymphoma:
Relapsed or Refractory Solid Tumors:
NKTR-262 is an investigational novel small molecule agonist designed to activate toll-like receptors (TLR 7/8), promoting TLR activation to induce the generation of antigen-specific cytotoxic T cells to the patient’s specific tumor.